免疫性血小板減少症患者の血小板機能活動
V V Bodrova1, S G Khaspekova1, O N Shustova1
1Chazov National Medical Research Center of Cardiology, Moscow, Russia.
Biomeditsinskaia khimiia
|September 4, 2025
まとめ
血小板活性化マーカーは,免疫性血小板減少症 (ITP) 患者,特に重度の出血患者において低下しています. この血小板機能の低下は,PAC- 1とCD62Pの結合の低下によって示され,自己抗体に関連している可能性があります.
科学分野:
- 血液学
- 免疫学
- 血小板生物学
背景:
- 免疫性血小板減少 (ITP) は,血小板数と血流の減少によって特徴付けられ,血小板数と血小板機能の両方に影響されます.
- 血小板の機能的活動は血静性において極めて重要であり,ITPにおけるその変化は完全に理解されていません.
- ITPにおける血小板機能障害を理解することは,出血合併症の管理の鍵です.
研究 の 目的:
- 健康なボランティアとITP患者の血小板機能の比較
- ITPにおける血小板活性化マーカー,自己抗体,および出血の重度の関係を調査する.
- 血小板表面マーカー表現に対する免疫性血小板減少の影響を調査する.
主な方法:
- 血小板活性化マーカー (活性化されたグリコタンパク質IIb-IIIaへのPAC- 1結合,Pセレクチンに対するCD62P) を評価するために,フロー細胞測定を用いた.
- 血小板は,トロンビン受容体活性化ペプチド (TRAP) またはADPを用いて活性化されました.
- 血小板関連IgG (PA-IgG),網状血小板 (RP,%) および血小板サイズも定量化した.
主要な成果:
- ITP患者はHVと比較してPAC- 1とCD62Pの結合が低かった.
- ITP患者では,PAC- 1結合がPA- IgG濃度と逆相関していた.
- ITPにおける重度の出血は,血小板数の減少,活性化マーカー結合の減少,およびPA- IgGとRP%の増加と関連していました.
結論:
- ITP患者では血小板活性化マーカーの発現が低下し,重度の出血の場合はさらに減少する.
- 自己抗体 (PA- IgG) は,グリコタンパク質IIb- IIIaに影響することで,血小板機能の低下に寄与する可能性があります.
- 血小板機能不全は ITPの出血症状に 影響を及ぼします
関連する概念動画
Structure and Function of Platelets
1.5K
The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
1.5K
Formation of the Platelet Plug
7.1K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
7.1K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
644
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
644


